2012 News Releases

2012 News Releases

Phase II Study Indicates that Fibrinogen Concentrate Given as a First-Line Therapy Safely Reduces Need for Transfusion after Aortic Surgery
19 Dec 2012

Clinical study results published today in the journal Anesthesiology showed that human fibrinogen concentrate can significantly reduce the need for blood transfusion when given as an intra-operative, targeted first-line hemostatic therapy in bleeding patients undergoing aortic replacement surgery.

CSL Behring Partners with Pro Supercross Racer Carl Schlacht to Encourage Those with Primary Immunodeficiency to be a “ChamPIon”
13 Dec 2012

CSL Behring has teamed up with Professional Supercross racer Carl Schlacht to launch www.IamaChamPIon.com. This new online resource is part of the I am a ChamPIon campaign, a partnership that aims to raise awareness of primary immunodeficiency disease (PI or PIDD) while encouraging those with the condition to pursue their dreams despite the challenges that PI can pose.

CSL Behring Parent Company, CSL Limited, Issues Fourth Corporate Responsibility Report
03 Dec 2012

CSL Behring’s parent company, CSL Limited (ASX:CSL), reaffirms the company’s commitment to responsible business practice and sustainable development in its fourth Corporate Responsibility Report – Our Corporate Responsibility 2012. The report details CSL’s performance across key corporate responsibility priority areas for the period July 1, 2011 through June 30, 2012.

Study Supports Efficacy, Safety of Hizentra® in Japanese Patients with Primary Immunodeficiency Disease
04 Oct 2012

A new study conducted in Japan supports the previously demonstrated safety and efficacy of Hizentra® (Immune Globulin Subcutaneous [Human]) for the treatment of primary immunodeficiency (PID). The data were presented today at the 15th Biennial Meeting of the European Society for Immunodeficiencies (ESID).

New Model Compares Economic Value of Subcutaneous Immunoglobulin Therapy with Intravenous Immunoglobulin
04 Oct 2012

Analysis using a new economic model demonstrates that higher dosing of subcutaneous immunoglobulin therapy (SCIg) is a cost-effective alternative to intravenous IgG replacement therapy (IVIG) in patients with primary immunodeficiencies (PID).

Avery-Landsteiner Prize for Immunology Awarded to Alain Fischer of Paris, France, by German Society for Immunology
07 Sep 2012

The German Society for Immunology (DGfI) has awarded its 2012 Avery-Landsteiner Prize to Alain Fischer, M.D., Ph.D., of Paris, France, for his milestone discoveries and treatment developments in the management of hereditary immunodeficiencies. The Prize was presented at the European Congress for Immunology in Glasgow, Scotland today.

Analysis Finds Improvements in Health-Related Quality of Life for Hereditary Angioedema Patients Treated with C1-Inhibitor
11 Aug 2012

A high level of health-related quality of life (HRQoL) is achievable for patients managing hereditary angioedema (HAE), a rare and serious genetic disorder, when effective treatment such as C1-inhibitor (INH) concentrate is available, according to a prospective patient assessment published recently in Allergy & Asthma Proceedings, the official journal of Regional, State & Local Allergy, Asthma and Immunology Societies (RSLAAIS) and the American Association of Certified Allergists (AACA). More than half of the HAE patients participating in the assessment reported feeling somewhat or much better with the availability of C1-INH concentrate, and more than 80 percent of participants indicated a more optimistic outlook on the future.

CSL Behring Awards Advocacy Grants to Patient Groups in Six States: NC, CA, WA, PA, IL, NY
01 Aug 2012

CSL Behring announced today that it has awarded six patient advocacy organizations in the U.S. with Local Empowerment for Advocacy Development (LEAD) grants totaling nearly $70,000. LEAD grants are awarded semiannually and are intended to help local patient organizations achieve their advocacy objectives by further developing an existing initiative or developing a new one.

Jeffrey Modell Foundation Opens Diagnostic Center for Primary Immunodeficiencies at Midwest Immunology Clinic
24 Jul 2012

The Jeffrey Modell Foundation (JMF), in partnership with CSL Behring, has designated the Midwest Immunology Clinic in Plymouth, Minnesota as a Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies (PI). The Center is headed by Ralph Shapiro, M.D. and is devoted to the diagnosis, treatment and care of people who have PI and autoimmune disorders.

CSL Behring Launches New Beriplex® P/N Dosing Calculator App for Healthcare Professionals on the Move
06 Jul 2012

Launch taking place at The General Anaesthetists in Training Annual Scientific Meeting 2012

CSL Behring Launches New Hizentra® Dosing Calculator App for Healthcare Professionals on the Move
06 Jul 2012

The mobile app, for use on smart phones, is designed to assist healthcare professionals with dosage calculation when administering Hizentra (human normal immunoglobulin, SCIg).

PRIMA Study Shows Treatment with Privigen® Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
27 Jun 2012

Data presented today from the Privigen Impact on Mobility and Autonomy (PRIMA) trial at the Peripheral Nerve Society Inflammatory Neuropathy Consortium Meeting in Rotterdam, Netherlands, suggests that treatment with Privigen® [Immune Globulin Intravenous (Human), 10% Liquid], an intravenous immunoglobulin (IVIg), may lead to improvement in function in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
08 Jun 2012

CSL Behring announced today that the company has been granted orphan drug designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).

CSL Behring Submits Marketing Authorization Variation Application to European Medicines Agency (EMA) for Privigen® in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
31 May 2012

CSL Behring announced today that it has submitted a Variation Application to the European Medicines Agency (EMA) for the use of Privigen® (immune globulin intravenous [human], 10 percent liquid for intravenous administration) in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). CIDP is a rare neurological disorder of the peripheral nerves characterized by symmetrical weakness in the arms and legs that progressively worsens for longer than two months. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne, Australia.

CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
29 May 2012

If approved by the FDA, the CSL Behring 4-factor PCC would be the first agent of its kind available in the United States.

CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase inhibitor in Patients with Hereditary Angioedema
03 May 2012

CSL Behring announced today that it has initiated an international phase I/II study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor (C1-INH) concentrate in patients with hereditary angioedema (HAE). Part of the COMPACT (Clinical Studies for Optimal Management in Preventing Angioedema with Low-Volume Subcutaneous C1-inhibitor Replacement Therapy) program, the study will evaluate the pharmacokinetics, pharmacodynamics and safety of various doses of this presentation of C1-INH.

Diagnosis Improves Quality of Life for Those With Bleeding Disorder
18 Apr 2012

As a little girl, Kristin Prior came to view what others may have seen as out of the ordinary as normal: The slightest tap or bump would result in a severe bruise and nosebleeds came often and without warning. As a teenager and into adulthood Kristin’s menstrual periods would be long, heavy and burdensome. Often these symptoms kept her from taking part in activities with friends and family or left her worried about what she might encounter when she did.

CSL Behring Renews Pledge to Provide Significant Funding and Donated Coagulation Factor to World Federation of Hemophilia Over 3-Year Period
16 Apr 2012

To mark World Hemophilia Day 2012, CSL Behring has again committed to making significant financial contributions and donations of clotting factor concentrate to the World Federation of Hemophilia (WFH) Global Alliance for Progress (GAP) program over the period of three years, beginning in 2012. The product donations will be made with medicine having a minimum shelf-life of one year. The goal of the WFH GAP program is to improve the diagnosis and treatment of hemophilia in developing countries. In 2009, CSL Behring was the first company to make such a three-year commitment to WFH. CSL Limited, parent company to CSL Behring, is committed to contributing to the economic, social and environmental well-being of its communities. As part of the agreement, CSL Behring will provide 2 million units of one or more of its various clotting factor products to the WFH each year for three years.

CSL Behring Commences Phase I study with rVIIa-FP, a Novel Therapy to Treat People With Hemophilia A and Hemophilia B Who Have Inhibitors
29 Mar 2012

CSL Behring announced today the first in human dosing of recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). The Phase I study will investigate in healthy volunteers the safety and pharmacokinetics of rVIIa-FP in comparison to placebo.